Business UpdateApr 24, 2026, 04:12 PM
Jazz Pharma Files Amended Annual Report for FY2025
AI Summary
Jazz Pharmaceuticals plc filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed its status as a well-known seasoned issuer and a large accelerated filer, indicating its compliance with SEC reporting requirements. This filing provides updated or corrected information to its previously submitted annual report.
Key Highlights
- Filed Form 10-K/A (Amendment No. 1) for fiscal year ended December 31, 2025.
- Confirmed status as a well-known seasoned issuer.
- Identified as a large accelerated filer.
- Compliant with Section 13 or 15(d) filing requirements.
Price Impact
More from JAZZ